Lin Deng, Lin Le, Ye Liefu, Li Tao, Wei Yongbao, Li Lizhi
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Department of Urology, Fujian Provincial Hospital South Branch, Fuzhou, China.
BMC Surg. 2024 May 3;24(1):134. doi: 10.1186/s12893-024-02430-2.
A considerable number of patients are diagnosed with prostate cancer (PCa) by transurethral resection of the prostate (TURP). We aimed to evaluate whether radical prostatectomy (RP) brings survival benefits for these patients, especially in the elderly with advanced PCa.
We used the Surveillance, Epidemiology, and End Results (SEER) database to obtain PCa cases diagnosed with TURP. After the propensity matching score (PSM) for case matching, univariate, multivariate, and subgroup analyses were performed to investigate whether RP impacts the survival benefit.
4,677 cases diagnosed with PCa by TURP from 2010 to 2019 were obtained, including 1,313 RP patients and 3,364 patients with no RP (nRP). 9.6% of RP patients had advanced PCa. With or without PSM, cancer-specific mortality (CSM) and overall mortality (OM) were significantly reduced in the RP patients compared to the nRP patients, even for older (> 75 ys.) patients with advanced stages (all p < 0.05). Except for RP, younger age (≤ 75 ys.), being married, and earlier stage (localized) contributed to a significant reduction of CSM risk (all p < 0.05). These survival benefits had no significant differences among patients of different ages, married or single, and at different stages (all p for interaction > 0.05).
Based on this retrospective population-matched study, we first found that in patients diagnosed with PCa by TURP, RP treatment may lead to a survival benefit, especially a reduction in CSM, even in old aged patients (> 75 ys.) with advanced PCa.
相当一部分前列腺癌(PCa)患者是通过经尿道前列腺切除术(TURP)确诊的。我们旨在评估根治性前列腺切除术(RP)是否能为这些患者带来生存益处,尤其是对于晚期PCa的老年患者。
我们使用监测、流行病学和最终结果(SEER)数据库获取经TURP确诊的PCa病例。在进行病例匹配的倾向评分匹配(PSM)后,进行单因素、多因素和亚组分析,以研究RP是否影响生存获益。
获得了2010年至2019年经TURP确诊为PCa的4677例病例,其中包括1313例接受RP治疗的患者和3364例未接受RP治疗(nRP)的患者。9.6%的RP患者患有晚期PCa。无论是否进行PSM,与nRP患者相比,RP患者的癌症特异性死亡率(CSM)和总死亡率(OM)均显著降低,即使是年龄较大(>75岁)的晚期患者也是如此(所有p<0.05)。除RP外,年龄较小(≤75岁)、已婚和早期阶段(局限性)有助于显著降低CSM风险(所有p<0.05)。这些生存获益在不同年龄、已婚或单身以及不同阶段的患者之间无显著差异(所有交互作用p>0.05)。
基于这项回顾性人群匹配研究,我们首次发现,在经TURP确诊为PCa的患者中,RP治疗可能带来生存获益,尤其是降低CSM,即使是晚期PCa的老年患者(>75岁)也是如此。